Blog

Douglas Flora: Sneak peek of my recent interview with Cliff Hudis in this month’s issue of AI in Precision Oncology

Photo of Douglas Flora and Cliff Hudis

Sep 25, 2024, 14:17

Douglas Flora: Sneak peek of my recent interview with Cliff Hudis in this month’s issue of AI in Precision Oncology

Douglas Flora shared a post on LinkedIn:

”I’m excited to share a sneak peek of my recent interview with Dr. Cliff Hudis, CEO of ASCO, in this month’s upcoming issue of AI in Precision Oncology. Cliff has been a personal oncology hero of mine since my early days as a breast cancer doctor, so it was a real honor to sit down with him.

During our conversation, Dr. Hudis offered some great insights on the responsible integration of AI in cancer care. Here’s one standout quote:

‘…we can start to gain meaningful efficiencies and improve the quality of our work and lives with these tools, as has happened outside of healthcare. Our slowness in this regard is frustrating but sadly consistent: It’s jaw-dropping insanity that the single biggest users of fax machines on Earth anymore are in American healthcare. It’s inefficient. It is insecure. So optimistically, I think we’re going to turn the corner, and things are going to get better. Our job, and what you’re trying to do here, is to educate people about what’s happening now and help us move this process along.’

Here is a link if you’d like to check out this piece and more at AI in Precision Oncology.”

Douglas Flora

Source: Douglas Flora/LinkedIn

Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.

As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.